PolyPid Provides Corporate Update and Reports Second Quarter 2022 Financial Results
Signed Exclusive L icensing A greement for C ommercialization of D-PLEX 100 in Europe for Potentially O ver $110 M illion in U pfront and M ilestone P ayments , Plus R oyalties on N et S ales I ndependent Data Safety Monitoring Board R ecommended C oncluding Phase 3 SHIELD I Trial of D-PLEX
